{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:44:40Z","timestamp":1790729080029,"version":"4.1.0"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.bioorg.2024.107775","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:13:53Z","timestamp":1725322433000},"page":"107775","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Cannabinoid receptor 2 (CB2) modulators: A patent review (2016\u20132024)"],"prefix":"10.1016","volume":"153","author":[{"given":"Rayees Ahmad","family":"Naikoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"Painuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaheen","family":"Akhter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvinder Pal","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bioorg.2024.107775_b0005","first-page":"180","article-title":"Medicinal cannabis: history, pharmacology, and implications for the acute care setting","volume":"42","author":"Bridgeman","year":"2017","journal-title":"P & T: Peer-Rev. J. Formul. Manag."},{"issue":"3","key":"10.1016\/j.bioorg.2024.107775_b0010","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/cre2.564","article-title":"A critical review of cannabis in medicine and dentistry: a look back and the path forward","volume":"8","author":"Abidi","year":"2022","journal-title":"Clin. Exp. Dent. Res."},{"issue":"227","key":"10.1016\/j.bioorg.2024.107775_b0015","doi-asserted-by":"crossref","first-page":"3s00","DOI":"10.1016\/j.jep.2018.09.004","article-title":"Cannabis sativa: a comprehensive ethnopharmacological review of a medicinal plant with a long history","volume":"5","author":"Bonini","year":"2018","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.bioorg.2024.107775_b0020","article-title":"Pharmacological and toxicological effects of phytocannabinoids and recreational synthetic cannabinoids: increasing risk of public health","volume":"14","author":"Bukke","year":"2021","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"issue":"7","key":"10.1016\/j.bioorg.2024.107775_b0025","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/j.1476-5381.2011.01536.x","article-title":"Themed issue on cannabinoids in biology and medicine","volume":"163","author":"Bab","year":"2011","journal-title":"Br. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.bioorg.2024.107775_b0030","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.biopsych.2015.07.028","article-title":"An introduction to the endogenous cannabinoid system","volume":"79","author":"Lu","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bioorg.2024.107775_b0035","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23071526","article-title":"Structure-activity relationship of cannabis derived compounds for the treatment of neuronal activity-related diseases","volume":"23","author":"Prandi","year":"2018","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"3","key":"10.1016\/j.bioorg.2024.107775_b0040","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19030833","article-title":"Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system","volume":"19","author":"Zou","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bioorg.2024.107775_b0045","doi-asserted-by":"crossref","first-page":"223","DOI":"10.31887\/DCNS.2020.22.3\/mcrocq","article-title":"History of cannabis and the endocannabinoid system","volume":"22","author":"Crocq","year":"2020","journal-title":"Dial. Clin. Neurosci."},{"issue":"11","key":"10.1016\/j.bioorg.2024.107775_b0050","article-title":"Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation","volume":"20","author":"Cabral","year":"2009","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.bioorg.2024.107775_b0055","first-page":"169","article-title":"CB(1) and CB(2) receptor pharmacology","volume":"80","author":"Howlett","year":"2017","journal-title":"Adv. Pharmacol. (San Diego, Calif.)"},{"key":"10.1016\/j.bioorg.2024.107775_b0060","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25040790","article-title":"Design, synthesis, and antimicrobial activities of 1,2,3-triazole glycoside clickers","volume":"25","author":"El Malah","year":"2020","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"6","key":"10.1016\/j.bioorg.2024.107775_b0065","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1210\/me.2015-1062","article-title":"Minireview: from the bench, toward the clinic: therapeutic opportunities for cannabinoid receptor modulation","volume":"29","author":"Picone","year":"2015","journal-title":"Mol. Endocrinol. (Baltimore, MD)"},{"issue":"4","key":"10.1016\/j.bioorg.2024.107775_b0070","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1124\/mol.114.094649","article-title":"CB2 Cannabinoid receptors as a therapeutic target-what does the future hold?","volume":"86","author":"Dhopeshwarkar","year":"2014","journal-title":"Mol. Pharmacol."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107775_b0075","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4155\/fmc.11.179","article-title":"Latest advances in novel cannabinoid CB(2) ligands for drug abuse and their therapeutic potential","volume":"4","author":"Yang","year":"2012","journal-title":"Fut. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2024.107775_b0080","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0304-3959(01)00321-9","article-title":"CB2 cannabinoid receptor-mediated peripheral antinociception","volume":"93","author":"Malan","year":"2001","journal-title":"Pain"},{"issue":"4","key":"10.1016\/j.bioorg.2024.107775_b0085","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/ACO.0000000000000616","article-title":"An overview of the cannabinoid type 2 receptor system and its therapeutic potential","volume":"31","author":"Bie","year":"2018","journal-title":"Curr. Opin. Anaesthesiol."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107775_b0090","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2174\/1389557514666140428105753","article-title":"Latest progress in the identification of novel synthetic ligands for the cannabinoid CB2 receptor","volume":"14","author":"Han","year":"2014","journal-title":"Mini Rev. Med. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2024.107775_b0095","article-title":"Cannabinoid receptors and their relationship with chronic pain: a narrative review","volume":"12","author":"Anthony","year":"2020","journal-title":"Cureus."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107775_b0100","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/sj.bjp.0707531","article-title":"Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain","volume":"153","author":"Guindon","year":"2008","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.bioorg.2024.107775_b0105","first-page":"989","article-title":"Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands","volume":"278","author":"Showalter","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107775_b0110","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0960-894X(95)00573-C","article-title":"Structure activity relationships of Tetrahydrocannabinol analogues on human Cannabinoid receptors","volume":"6","author":"Gareau","year":"1996","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107775_b0115","first-page":"1","article-title":"Pharmacological actions of cannabinoids","volume":"168","author":"Pertwee","year":"2005","journal-title":"Springer Berlin Heidelberg"},{"issue":"11","key":"10.1016\/j.bioorg.2024.107775_b0120","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1021\/jm061195+","article-title":"2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro2H-pyran-4-yl)methyl]-4-(trifluoromethyl)-5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain","volume":"50","author":"Giblin","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107775_b0125","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1016\/j.bmcl.2012.02.072","article-title":"Discovery of S-777469: an orally available CB2 agonist as an antipruritic agent","volume":"22","author":"Odan","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107775_b0130","article-title":"The structure\u2013function relationships of classical cannabinoids: CB1\/CB2 modulation","volume":"8","author":"Bow","year":"2016","journal-title":"Perspect. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107775_b0135","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1124\/pharmrev.122.000600","article-title":"Goods and bads of the endocannabinoid system as a therapeutic target: lessons learned after 30 years","volume":"75","author":"Maccarrone","year":"2023","journal-title":"Pharmacol. Rev."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107775_b0140","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/sj.bjp.0707568","article-title":"In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models","volume":"153","author":"Yao","year":"2008","journal-title":"Br. J. Pharmacol."},{"issue":"12","key":"10.1016\/j.bioorg.2024.107775_b0145","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1021\/acsmedchemlett.7b00396","article-title":"Discovery of APD371: identification of a highly potent and selective CB(2) agonist for the treatment of chronic pain","volume":"8","author":"Han","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107775_b0150","unstructured":"A. Roland, M. Blanco, et al., Formulation of cannabidiol derivative and its use as a modulator of cannabinoid receptor type 2 (CB2), JP2022519685A, 2020."},{"key":"10.1016\/j.bioorg.2024.107775_b0155","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1426446","article-title":"RG7774 (Vicasinabin), an orally bioavailable cannabinoid receptor 2 (CB2R) agonist, decreases retinal vascular permeability, leukocyte adhesion, and ocular inflammation in animal models","volume":"15","author":"Grether","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"13","key":"10.1016\/j.bioorg.2024.107775_b0160","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1016\/j.bmc.2014.04.062","article-title":"Ultrapure ajulemic acid has improved CB2 selectivity with reduced CB1 activity","volume":"22","author":"Tepper","year":"2014","journal-title":"Bioorg. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2024.107775_b0165","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4155\/ppa-2021-0002","article-title":"Cannabinoid receptor type 2 ligands: an analysis of granted patents since 2010","volume":"10","author":"Brennecke","year":"2021","journal-title":"Pharm. Pat. Anal."},{"issue":"10","key":"10.1016\/j.bioorg.2024.107775_b0170","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/cmdc.200900226","article-title":"2,3-Dihydro-1-benzofuran derivatives as a series of potent selective cannabinoid receptor 2 agonists: design, synthesis, and binding mode prediction through ligand-steered modeling","volume":"4","author":"Diaz","year":"2009","journal-title":"ChemMedChem: Chem. Enabl. Drug Discov."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107775_b0175","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1124\/jpet.302.1.359","article-title":"Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties","volume":"302","author":"Mauler","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107775_b0180","article-title":"TT-816, a novel small molecule immune checkpoint inhibitor targeting cannabinoid CB2 receptor, stimulates innate and adaptive immunity for cancer therapy","volume":"10","author":"Fan","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.bioorg.2024.107775_b0185","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1152\/physrev.00002.2016","article-title":"From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology","volume":"96","author":"Ligresti","year":"2016","journal-title":"Physiol. Rev."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107775_b0190","doi-asserted-by":"crossref","DOI":"10.3390\/cells10051199","article-title":"Modulation of endocannabinoid tone in osteoblastic differentiation of MC3T3-E1 cells and in mouse bone tissue over time","volume":"10","author":"Kostrzewa","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2024.107775_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109025","article-title":"A selective CB(2) agonist protects against the inflammatory response and joint destruction in collagen-induced arthritis mice","volume":"116","author":"Bai","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.bioorg.2024.107775_b0200","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21030747","article-title":"The endocannabinoid system: a target for cancer treatment","volume":"21","author":"Laezza","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107775_b0205","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1158\/1940-6207.CAPR-10-0181","article-title":"Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis","volume":"4","author":"Preet","year":"2011","journal-title":"Cancer Prev. Res. (Phila.)"},{"key":"10.1016\/j.bioorg.2024.107775_b0210","article-title":"Cannabinoid ligands targeting TRP channels","volume":"11","author":"Muller","year":"2018","journal-title":"Front. Mol. Neurosci."},{"issue":"4","key":"10.1016\/j.bioorg.2024.107775_b0215","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.cell.2020.01.007","article-title":"Cryo-EM structure of the human cannabinoid receptor CB2-Gi signaling complex","volume":"180","author":"Xing","year":"2020","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.bioorg.2024.107775_b0220","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/13543776.2016.1193157","article-title":"Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update","volume":"26","author":"Morales","year":"2016","journal-title":"Expert Opin. Ther. Pat."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107775_b0225","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1517\/13543776.2012.682570","article-title":"Selective cannabinoid receptor 2 modulators: a patent review 2009 - present","volume":"22","author":"Riether","year":"2012","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bioorg.2024.107775_b0230","unstructured":"U. Grether, M. Nettekoven, M. Rogers-Evans, et al., Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2, WO\/2016\/071375, 2016."},{"key":"10.1016\/j.bioorg.2024.107775_b0235","unstructured":"L. Gobbi, U. Grether, W. Guba, et al., Novel[1,2,3]triazolo[4,5-d]pyrimidine derivatives, WO\/2018\/015088, 2018."},{"key":"10.1016\/j.bioorg.2024.107775_b0240","unstructured":"L. Gobbi, U. Grether, W. Guba, et al., [1,2,3]triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor, WO\/2017\/220517, 2017."},{"key":"10.1016\/j.bioorg.2024.107775_b0245","unstructured":"L. Gobbi, U. Grether, W. Guba, et al., Novel [1,2,3-triazolo[4,5-d]pyrimidine derivatives, WO\/2017\/220544A1, 2017."},{"key":"10.1016\/j.bioorg.2024.107775_b0250","unstructured":"O. Gavelle, U. Grether, M. Nettekoven, et al., Phenyl derivatives as cannabinoid receptor 2 agonists, WO\/2017\/097732, 2017."},{"key":"10.1016\/j.bioorg.2024.107775_b0255","unstructured":"S.M. Ametamey, L. Gobbi, U. Grether, et al., Novel azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2, WO\/2020\/002280, 2020."},{"key":"10.1016\/j.bioorg.2024.107775_b0260","unstructured":"L. Gobbi, U. Grether, J. Kretz, et al., Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2, WO\/2020\/002320, 2020."},{"key":"10.1016\/j.bioorg.2024.107775_b0265","unstructured":"S. Anavi-Goffer, J. Gertsch, CB2 receptor ligands for the treatment of psychiatric disorders, US\/2016\/0089349, 2016."},{"key":"10.1016\/j.bioorg.2024.107775_b0270","unstructured":"S. Anavi-Goffer, Treatment of mental, movement and behavioral disorders, WO\/2018\/112138, 2018."},{"key":"10.1016\/j.bioorg.2024.107775_b0275","unstructured":"S. Anavi-Goffer, Compositions of CB2 receptor selective agonists for treatment of mental disorders, WO\/2017\/149387, 2017."},{"key":"10.1016\/j.bioorg.2024.107775_b0280","unstructured":"X.-Q. Xie, A.R. Almehizia, P. Yang, Novel cannabinoid receptor CB2 ligand 4-(aminomethyl)-N,N-dialkylanilines, WO\/2016\/205707, 2016."},{"key":"10.1016\/j.bioorg.2024.107775_b0285","unstructured":"M. Lynch, M. Kelly, Use of cannabinoids in the treatment of ocular inflammation and\/or pain, WO\/2016\/187722, 2016."},{"key":"10.1016\/j.bioorg.2024.107775_b0290","unstructured":"R.O. Pol, Use of heme oxygenase 1 inducers and cannabinoid 2 receptor or delta-opioid receptor agonists in inflammatory pain, EP2992880, 2016."},{"key":"10.1016\/j.bioorg.2024.107775_b0295","unstructured":"T.W. Klein, C. Newton, C. Patterson, et al., Methods and compositions for reducing serum levels of immunoglobulin E (IGE), US9289421B2, 2016."},{"key":"10.1016\/j.bioorg.2024.107775_b0300","unstructured":"W. Shanahan, Methods of treatment with selective CB2 receptor agonists, WO\/2017\/180528, 2017."},{"key":"10.1016\/j.bioorg.2024.107775_b0305","unstructured":"J. Thatte, A.C. Blackburn, S. Han, et al., Cannabinoid receptor modulators, US11771695B2, 2023."},{"key":"10.1016\/j.bioorg.2024.107775_b0310","unstructured":"M. Tepper, D.A. Frey, D. Goeddel, et al., Ultrapure Tertrahydrocannabinol-11-oic acids, US10154986B2, 2018."},{"key":"10.1016\/j.bioorg.2024.107775_b0315","unstructured":"A. AizikovichI, Cannabinolic acid derivative and uses thereof, WO\/2019\/234728, 2019."},{"key":"10.1016\/j.bioorg.2024.107775_b0320","unstructured":"A. Aizikovich, Tetrahydrocannabinolic-Cannabinolic acid derivatives and uses thereof, US\/2021\/0087159, 2021."},{"key":"10.1016\/j.bioorg.2024.107775_b0325","unstructured":"A.G. Hohmann, K.P. Mackie, X. Lin, et al., Methods of using cannabinoid CB2 receptor agonist compositions to supress and prevent opioid tolerance and withdrawal in a subject, US\/2019\/0314379, 2019."},{"key":"10.1016\/j.bioorg.2024.107775_b0330","unstructured":"O. Hazan, Use of CB2 inhibitors for lymphocyte recovery, WO\/2019\/207582, 2019."},{"key":"10.1016\/j.bioorg.2024.107775_b0335","unstructured":"D.L. Silver, M. Ahmed, S.Y.F. Mak, Anandamide compounds, WO\/2020\/146771, 2020."},{"key":"10.1016\/j.bioorg.2024.107775_b0340","unstructured":"B.G. Reid, J.M. Cooper, Compositions and methods for agonizing the CB2 receptor, WO\/2020\/000103A1, 2020."},{"key":"10.1016\/j.bioorg.2024.107775_b0345","unstructured":"S. Ahmar, J.Y. Kim, P.S. Lai, et al., Cannabinoid derivatives, WO\/2021\/102568, 2021."},{"key":"10.1016\/j.bioorg.2024.107775_b0350","unstructured":"Z.D. Berneman, A.M. Eyal, Dental care cannabis device and use thereof, US\/2021\/0093561, 2021."},{"key":"10.1016\/j.bioorg.2024.107775_b0355","unstructured":"S.K. Meegalla, M.R. Player, Hexahydro-5,8-epoxycyclohepta[c]pyrazole derivatives useful as modulators of the CB1 and\/or CB2 receptors, WO\/2021\/069671, 2021."},{"key":"10.1016\/j.bioorg.2024.107775_b0360","unstructured":"D. Mukherjea, V. Ramkumar, L. Rybak, Regimens, compositions and methods with capsaicin and TNF-alpha inhibitor, US\/2021\/0253689, 2021."},{"key":"10.1016\/j.bioorg.2024.107775_b0365","unstructured":"E. Schuchman, C.M. Simonaro, Compositions and methods for activating signalling through the CB2 cannabinoid receptor for treating and preventing lysosomal storage diseases and disorders, WO\/2021\/236890, 2021."},{"key":"10.1016\/j.bioorg.2024.107775_b0370","unstructured":"G. Amato, M. Rangan, S. Runyon, Indazole derivatives as cannabinoid receptor partial agonists, WO\/2021\/155227, 2021."},{"key":"10.1016\/j.bioorg.2024.107775_b0375","unstructured":"G. Amato, R. Maitra, S.P. Runyon, Indazole derivatives as cannabinoid receptor partial agonists, US\/2023\/0339863A1, 2023."},{"key":"10.1016\/j.bioorg.2024.107775_b0380","unstructured":"J. Tam, A. Goldblum, S. El-Atawneh, et al., Novel peripheral cannabinoid-1 receptor antagonists, WO\/2021\/024260, 2021."},{"key":"10.1016\/j.bioorg.2024.107775_b0385","unstructured":"E. Elzein, J. Liu, Cannabinoid receptor type 2 (CB2) modulators and uses thereof, WO\/2021\/226206, 2021."},{"key":"10.1016\/j.bioorg.2024.107775_b0390","unstructured":"C. Liming, Z. Rongrong, Z. Yanjing, et al., A mesenchymal stem cell exosome-AM1241 complex and its application in the treatment of Alzheimer's disease patent, CN113181216A, 2021."},{"key":"10.1016\/j.bioorg.2024.107775_b0395","unstructured":"Z. Caibin, 11-O-mogroside V and pharmaceutically acceptable salts thereof cosmetic application as CB2 receptor agonist, CN114404315A, 2022."},{"key":"10.1016\/j.bioorg.2024.107775_b0400","unstructured":"N. Eshel, M. Green, A. Jahangir, et al., CB2 receptor agonists, WO\/2022\/132803, 2022."},{"key":"10.1016\/j.bioorg.2024.107775_b0405","unstructured":"A. Yates, P. Dickinson, R. Ward, Pharmaceutical compositions comprising cannabinoid agonist, WO\/2022\/123233, 2022."},{"key":"10.1016\/j.bioorg.2024.107775_b0410","unstructured":"Y. Inami, Y. Okumua, T. Walker, Stable salt and crystal forms of 2-[3-({1-[2-(dimethylamino)ethyl]-2-(2,2-dimethylpropyl)-1H-1,3-benzodiazol-5-yl}sulphonyl)azetidin-1-yl]ethanol-1-ol, WO\/2022\/102713, 2022."},{"key":"10.1016\/j.bioorg.2024.107775_b0415","unstructured":"D. Smith, B. Mitrasca, P. Kujawa, et al., Dual analgesic\/anti-inflammatory compositions comprising CB2 receptor agonists, combinations, and methods of use thereof, WO\/2022\/036455, 2022."},{"key":"10.1016\/j.bioorg.2024.107775_b0420","unstructured":"D. Smith, B. Mitrasca, P. Kujawa, et al., Dual analgesic\/anti-inflammatory compositions comprising CB2 receptor agonists, combinations, and methods of use thereof, US\/2024\/0016762A1, 2024."},{"key":"10.1016\/j.bioorg.2024.107775_b0425","unstructured":"M.M.A. Moustafa, Cannabinoid sulfate esters, their salts and uses thereof, US\/2023\/0339850A1, 2023."},{"key":"10.1016\/j.bioorg.2024.107775_b0430","unstructured":"M. Ridall, V.T. Mileto, Use of cannabinoids in the treatment of Tourette syndrome and tic disorders, US\/2024\/0000810A1, 2024."},{"key":"10.1016\/j.bioorg.2024.107775_b0435","unstructured":"J.R. Williams, Synthetic Cannabinoid compounds, Pharmaceutical compositions and treatment methods, WO\/2023\/096918A1, 2023."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824006801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824006801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T02:21:07Z","timestamp":1738203667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206824006801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":87,"alternative-id":["S0045206824006801"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107775","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabinoid receptor 2 (CB2) modulators: A patent review (2016\u20132024)","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107775","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107775"}}